Cytokines and the adrenal cortex: Basic research and clinical implications

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 3, 2000, Pages 128-137

  Bornstein, Stefan R ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; PRASTERONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL CORTEX; ADRENAL CORTEX TUMOR; ADRENAL GLAND; HUMAN; HYPERADRENOCORTICISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; REVIEW; SEPSIS;

EID: 0034079750     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200006000-00005     Document Type: Review

References (105)

1. 1 Chrousos GP: Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998, 851:311-335.
2. 2 Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP: Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998, 19(2):101-143.
3. 3 Elenkov IJ, Webster EL, Torpy DJ, Chrousos GP: Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. In: Neuroendocrine Immune Basis of the Rheumatic Diseases. Edited by Cutolo M. New York: New York Academy of Sciences, 1999:876.
4. 4 Sternberg EM: Neural-immune interactions in health and disease. J Clin Invest 1997, 100(11):2641-2647.
5. 5 Besedovsky HO, del Rey A: Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996, 17:64-102.
6. 6 Reichlin S: Neuroendocrine-immune interactions. N Engl J Med 1993, 329:1246-1253.
7. 7 Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1998;332:1351-1362.
8. 8 Marx C, Ehrhart-Bornstein M, Scherbaum WA, Bornstein SR: Regulation of adrenocortical function by cytokines: relevance for immune-endocrine interaction. Horm Metab Res 1998, 30:416-420. This review summarizes current knowledge on production, action, and functional implications of cytokine action within the adrenal gland.
9. 9 Judd AM: Cytokine expression in the rat adrenal cortex. Horm Metab Res 1998, 30:404-410.
10. 10 Wolkersdörfer GW, Lohmann T, Schröder S, Marx C, Pfeiffer R, Stahl H-D, Scherbaum WA, Chrousos GP, Bornstein SR: Lymphocytes stimulate dehydroepiandrosterone production through direct cellular contact with adrenal zona reticularis celts: a novel mechanism of immune-endocrine interaction. J Clin Endocrinol Metab 1999, 84(11):1-8. T cells within the adrenal gland have direct cell-cell contact with epithelial cells of the adrenal zona reticularis. This provides a mechanism for immune system-mediated stimulation of androgen secretion in vitro and helps explain how impaired T cell function results in decreased androgen levels in vivo. Also, it provides evidence for a non-ACTH-mediated mechanism of adrenocortical androgen regulation. These findings may provide an evidence-based strategy for DHEA treatment in some disorders of the immune system. Patients with systemic lupus erythematosus, rheumatoid arthritis, and AIDS have low DHEA levels and might benefit from such treatment.
11. 11 Yirmiya R, Weidenfeld J, Barak O, et al.: The role of brain cytokines in mediating the behavioral and neuroendocrine effects of intracerebral Mycoplasma fermentans. Brain Res 1999, 829(1-2):28-38. Findings indicate that both TNF-α and IL-1 participate in mediating some of the behavioral effects of infection with Mycoplasma fermentans, whereas only TNF-α, but not IL-1, is involved in mediating M. fermentans-induced adrenocortical activation. Suggests that cytokines within the brain are involved in mediating at least some of the neurobehavioral and neuroendocrine abnormalities that may be produced by M. fermentans in AIDS patients.
12. 12 Wang J, Dunn AJ: The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1. Brain Res 1999, 815:337-348.
13. 13 Turnbull AV, Rivier CL: Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999, 79(1):1-71.
14. 14 Horai R, Asano M, Sudo K, et al.: Production of mice deficient in genes for interleukin (IL)-1 alpha, IL-1 beta, IL-1 alpha/beta, and IL-1 receptor antagonist shows that IL-1 beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998, 187:1463-1475.
15. 15 Ray D, Melmed S: Pituitary cytokine and growth factor expression and action. Endocr Rev 1997, 18:206-228.
16. 16 Turnbull AV, Smith GW, Lee S, et al.: CRF type 1 receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Endocrinology 1999, 140(2):1013-1017. Resting ACTH secretion in CRF-R1 -/-mice is in part attributable to AVP-dependent mechanisms; and whereas in normal mice the pituitary-adrenal response to local inflammation is mediated largely via CRF-dependent mechanisms, mice deficient in CRF-R1 are still able to mount a pituitary-adrenal response via mechanisms that do not depend critically on either CRF or AVP action.
17. 17 Arzt E, Paez Pereda M, Costas M, et al.: Cytokine expression and molecular mechanisms of their auto/paracrine regulation of anterior pituitary function and growth. Ann NY Acad Sci 1998, 840:525-531.
18. 18 Kobayashi H, Fukata J, Murakami N, et al.: Tumor necrosis factor receptors in the pituitary cells. Brain Res 1997, 758(1-2):45-50.
19. 19 Akita S, Webster J, Ren SG, et al.: Human and murine pituitary expression of leukemia inhibitory factor. J Clin Invest 1995, 95:1288-1298.
20. 20 Wang Z, Ren S-G, Melmed S: Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuroendocrine interface. Endocrinology 1996, 137:2947-2953.
21. 21 Auernhammer CJ, Chesnokova V, Melmed S: Leukemia inhibitory factor (LIF) modulates IL-1? induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 1998, 139:2201-2208.
22. 22 Shimon I, Van X, Ray DW, Melmed S: Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. J Clin Invest 1997, 100:357-363.
23. 23 Ray DW, Ren SG, Melmed S: Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996, 97:1852-1859.
24. 24 Auernhammer CJ, Chesnokova V, Bousquet C, Melmed S: Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol Endocrinol 1998, 12:954-961.
25. 25 Ra DW, Ren SG, Melmed S: Leukemia inhibitory factor regulates proopiomelanocortin transcription. Ann Ny Acad Sci 1998, 840:162-173.
26. 26 Chesnokova V, Auernhammer CJ, Melmed S: Murine leukemia inhibitory factor (LIF) gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 1998, 139:2201-2208.
27. 27 Akita S, Readhead C, Stefaneanu L, et al.: Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs pituitary function: a model for human pituitary Rathke's cysts. J Clin Invest 1997, 99:2462-2469.
28. 28 Yano H, Readhead C, Nakashima M, Ren S-G, Melmed S: Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. Mol Endocrinol 1998, 12:1708-1720.
29. 29 Auernhammer CJ, Melmed S: Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Endocrinology 1999, 140(4):1559-1566. Interleukin-11 regulates the HPA axis similarly to LIF, providing further evidence for a redundant cytokine network in the neuro-immuno-endocrine regulation of the HPA axis.
30. 30 Kapcala LP, He JR, Gao Y, Pieper JO, DeTolla LJ: Subdiaphragmic vagotomy inhibits intra-abdominal interleukin-1β stimulation of adrenocorticotropin secretion. Brain Res 1996, 728:247-254.
31. 31 Andreis PG, Neri G, Belloni AS, Mazzocchi G, Kasprzak A, Nussdorfer GG: Interleukin-1 β enhances corticosterone secretion by acting directly on the rat adrenal gland. Endocrinology 1991, 129(1):53-57.
32. 32 Roh MS, Drazenovich KA, Barbose JJ, Dinarello CA, Cobb CF: Direct stimulation of the adrenal cortex by interleukin-1. Surgery 1987, 102:140-146.
33. 33 Whitcomb RW, Linehan WM, Wahl LM, Knazek RA: Monocytes stimulate cortisol production by cultured human adrenocortical cells. J Clin Endocrinol Metab 1988, 66:33-38.
34. 34 Andreis PG, Neri G, Meneghelli V, Mazzocchi G, Nussdorfer GG: Effects of interleukin-1 beta on the renin-angiotensin-aldosterone system in rats. Res Exp Med 1992, 192:1-6.
35. 35 Natarajan R, Ploszaj S, Horton R, Nadler J: Tumor necrosis factor and interleukin-1 are potent inhibitors of angiotensin II-induced aldosterone synthesis. Endocrinology 1989, 125:3084-3089.
36. 36 Winter JSD, Gow KW, Perry YS, Greenberg HA: A stimulatory effect of interleukin-1 on adrenocortical cortisol secretion mediated by prostaglandins. Endocrinology 1990, 127(4):1904-1909.
37. 37 Tominaga T, Fukata J, Naito Y, et al.: Prostaglandin dependent in vitro stimulation of adrenal steroidogenesis by interleukins. Endocrinology 1991, 128(1):526-531.
38. 38 Gwosdow AR, O'Connell NA, Spencer JA, et al.: Interleukin-1-induced corticosterone release occurs by an adrenergic mechanism from rat adrenal gland. Am J Physiol Endocrinol Metab 1992, 263:E461-466.
39. 39 O'Connell NA, Kumar A, Chatzipanteli K, et at.: Interleukin-1 regulates corticosterone secretion from the rat adrenal gland through a catecholamine-dependent and prostaglandin E2-independent mechanism. Endocrinology 1994, 135:460-467.
40. 40 Tominaga T, Fukata J, Fujimoto T, et al.: Immunocytochemical evidence for interteukin-2 receptor regulation on rat anterior pituitary and adrenal cells. Acta Histochem Cytochem 1996, 29:255-260.
41. 41 Weber MM, Michl P, Auernhammer CJ, Engelhardt D: Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells. Endocrinology 1997, 138:2207-2210.
42. 42 Salas MA, Evans SW, Levell MJ, Whicher JT: Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 1990, 79:470-473.
43. 43 Späth-Schwalbe E, Born J, Schrezenmeier H, et al.: Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994, 79:1212-1214.
44. 44 Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA: Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997, 82:2343-2349.
45. 45 Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, Luger A: Interferon-α stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993, 57:489-495.
46. 46 Ilvesmaki V, Jaattela M, Saksela E, Voutilainen R: Tumor necrosis factor-alpha and interferon-gamma inhibit insulin-like growth factor II gene expression in human fetal adrenal cell cultures. Mol Cell Endocrinol 1993, 91:59-65.
47. 47 Voutilainen R, Ilvesmaki V, Ariel I, et al.: Parallel regulation of parentally imprinted H19 and insulin-like growth factor-II genes in cultured human fetal adrenal cells. Endocrinology 1994, 134:2051-2056.
48. 48 Tachikawa E, Itho K, Kudo K, et al.: Effects of interferons on cortisol production in bovine adrenal fasciculata cells stimulated by adrenocorticotropin. J Pharm Pharmacol 1999, 51:465-473. Recombinant IFN-α-2b from humans, but not fibroblast IFN-β and recombinant IFN-γ from humans, reduced ACTH-induced production of cortisol in bovine adrenal fasciculata cells by affecting an early step in the process of cortisol synthesis. However, IFN-α might not directly affect glucocorticoid production in the adrenal cortex in vivo, because of the high IFN-α-2b concentrations required for inhibition.
49. 49 Swain MG, Maric M: Tumor necrosis factor-α stimulates adrenal glucocorticoid secretion in cholestatic rats. Am J Physiol Gastrointest Liver Physiol 1996, 270:G987-991.
50. 50 Jäättelä M, Ilvesmaki V, Voutilainen R, et al.: Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991, 128:623-629.
51. 51 Jäättelä M, Carpén O, Stenman U-H, Saksela E: Regulation of ACTH-induced steroidogenesis in human fetal adrenals by rTNF-α. Mol Cell Endocrinol 1990, 68:R31-36.
52. 52 Thompson NL, Flanders KC, Smith JM, et al.: Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989, 108:661-669.
53. 1 in the bovine adrenal cortex using antipeptide antibodies. Endocrinology 1991, 129:517-526.
54. 54 Feige JJ, Negoescu A, Keramidas M, et al.: Alpha(2)-macroglobulin-a binding-protein for transforming growth-factor-beta and various cytokines. Horm Res 1996, 45:227-232.
55. 55 Chambaz EM, Souchelnitskiy S, Pellerin S, et al.: Transforming growth factor-β - a multifunctional cytokine family-implication in the regulation of adrenocortical cell endocrine functions. Horm Res 1996, 45:222-226.
56. 1 mRNAs in the rat adrenal cortex. Growth Hormone IGF Res 1999, 9:41-51. An increase in adrenocortical growth resulting from ACTH treatment is associated with an increase in insulin-like growth factor-I mRNA expression but only a transient increase in TGF-β1 mRNA expression.
57. 57 Feige JJ, Cochet C, Savona C, Shi DL, Keramidas M, Defaye G, Chambaz EM: Transforming growth factor β1: an autocrine regulator of adrenocortical steroidogenesis. Endocr Res 1991, 17:267-279.
58. 58 Cochet C, Feige JJ, Chambaz EM: Bovine adrenocortical cells exhibit high affinity transforming growth factor-β receptors which are regulated by adrenocorticotropin. J Biol Chem 1988, 263:5707-5713.
59. 59 Le Roy C, Leduque P, Dubois PM, Saez JM, Langlois D: Repression of transforming growth factor beta 1 proteinb by antisense oligonucleotide-induced increase of adrenal cell differentiated functions. J Biol Chem 1996, 271:11027-11033.
60. 60 Hotta M, Baird A: Differential effects of transforming growth factor type β on the growth and function of adrenocortical cells in vitro. Proc Natl Acad Sci USA 1986, 83:7795-7799.
61. 61 Rainey WE, Viard I, Mason JI, et al.: Effects of transforming growth factor beta on ovine adrenocortical cells. Mol Cell Endocrinol 1988, 60:189-198.
62. 1 is a negative regulator of steroid 17α-hydroxylase in bovine adrenocortical cells. Endocrinology 1990, 128:357-362.
63. 63 Rainey WE, Naville D, Saez JM, et al.: Transforming growth factor-β inhibits steroid 17α-hydroxylase cytochrome P-450 expression in ovine adrenocortical cells. Endocrinology 1990, 127:1910-1915.
64. 64 Molenaar WM, Lee V-M, Trojanowski JQ: Early fetal acquisition of the chromaffin and neuronal immunophenotype by human adrenal medullary cells: an immunohistological study using monoclonal antibodies to chromogranin A, synaptophysin, tyrosin hydroxylase and neuronal cytoskeletal proteins. Exp Neurol 1990, 108:1-9.
65. 65 Rainey WE, Viard I, Saez JM: Transforming growth factor β treatment decreases ACTH receptors on ovine adrenocortical cells. J Biol Chem 1989, 264:21474-21477.
66. 66 Stankovic AK, Dion LD, Parker CR Jr: Effects of transforming growth factor-beta on human fetal adrenal steroid production. Mol Cell Endocrinol 1994, 99:145-151.
67. 67 Burt DW, Paton IR: Evolutionary origins of the transforming growth factor-β gene family. DNA Cell Biol 1992, 11:497-510.
68. 68 Lebrethon MC, Jaillard C, Naville D, Begeot M, Saez JM: Effects of transforming growth factor-β1 on human adrenocortical fasciculata-reticularis cell differentiated functions. J Clin Endocrinol Metab 1994, 79:1033-1039.
69. 69 Parker CR, Stankovic AK, Faye-Petersen O, et al.: Effects of ACTH and cytokines on dehydroepiandrosterone sulfotransferase messenger RNA in human adrenal cells. Endocrine Res 1998, 24(3&4):669-673. Cellular levels of dehydroepiandrosterone sulfotransferase (DST) mRNA were increased in a dose-dependent fashion in response to ACTH; DST mRNA was less responsive to ACTH stimulation than was 17 hydroxylase (CYP 17) mRNA. The stimulatory effects of ACTH on DST mRNA levels were blunted by both TGF-beta and TNF-alpha; the inhibitory effects of TNF-α on DST mRNA were more striking than were those on CYP 17 mRNA. These data suggest that DST production can be altered by several agents acting on the DST gene.
70. 70 Gonzalez-Hernandez JA, Ehrhart-Bornstein M, Späth-Schwalbe E, et al.: Human adrenal cells express TNF α-mRNA: evidence for a paracrine control of adrenal function. J Clin Endocrinol Metab 1996, 81:807-813.
71. 71 Gonzalez-Hernandez JA, Bornstein SR, Ehrhart-Bornstein M, et al.: Interleukin 1 is expressed in human adrenal gland in vivo: Possible role in a local immune-adrenal axis. Clin Exp Immunol 1995, 99:137-141.
72. 72 Gonzalez-Hernandez JA, Bornstein SR, Ehrhart-Bornstein M, et al.: Interleukin-6 mRNA expression in human adrenal gland in vivo: new clue to a paracrine or autocrine regulation of adrenal function. J Clin Endocrinol Metab 1994, 79:1492-1497.
73. 73 Nathan CF: Secretory products of macrophages. J Clin Invest 1987, 79:319-326.
74. 74 Assoian RK, Fleurdelys BE, Stevenson HC, et al.: Expression and secretion of type β transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987, 84:6020-6024.
75. 75 Mathison JC, Schreiber RD, La Forest AC, Ulevitch RJ: Suppression of ACTH-induced steroidogenesis by supernatants from LPS-treated peritoneal exudate macrophages. J Immunol 1983, 130:2757-2762.
76. 76 Mathison JC, La Forest AC, Ulevitch RJ: Properties and requirements for production of a macrophage product which suppresses steroid production by adrenocortical cells. Infect Immun 1984, 45:360-366.
77. 77 Merke DP, Bornstein SR, Braddock D, Chrousos GP: Adrenal lymphocytic infiltration and adrenocortical tumors in a patient with 21-hydroxylase deficiency. N Engl J Med 1999, 340(14):1121-1122.
78. 78 Marx C, Bornstein SR, Wolkersdörfer GW, et al.: Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differnetiation in the human adrenal cortex. J Clin Endocrinol Metab 1997, 82:3136-3140.
79. 79 Hayashi Y, Hiyoshi T, Takemura T, et al.: Focal lymphocytic infiltration in the adrenal cortex of the elderly: immunohistological analysis of infiltrating lymphocytes. Clin Exp Immunol 1989, 77:101-105.
80. 80 Judd AM, Spangelo BL, MacLeod RM: Rat adrenal zona glomerulosa cells produce interleukin-6. Prog Neuro Endocrin Immunol 1990, 3:282-292.
81. 81 Judd AM, MacLeod RM: Differential release of tumor necrosis factor and IL-6 from adrenal zona glomerulosa cells in vitro. Am J Physiol 1992, 68:E114-120.
82. 82 Judd AM, MacLeod RM: Angiotensin II increases interleukin 6 release from rat adrenal zona glomerulosa cells. Prog Neuro Endocrin Immunol 1991, 4:240-247.
83. 83 Judd Am, MacLeod RM: Adrenocorticotropin increases interleukin-6 release from rat adrenal zona glomerulosa cells. Endocrinology 1992, 130:1245-1254.
84. 84 Conti B, Jahng JW, Tinti C, Son JH, Joh TH: Induction of interferon-gamma inducing factor in the adrenal cortex. J Biol Chem 1997, 272:2035-2037.
85. 85 Khoury EL, Greenspan JS, Greenspan FS: Adrenocortical cells of the zona reticularis normally express HLA-DR antigenic determinants. Am J Pathol 1987, 127:580-591.
86. 86 Wolkersdörfer G, Marx C, Lohmann T, et al.: The mercy of adrenocortical tumor cells on lymphocytes. Endocrine Res 1998, 24(3&4):711-716. Immune escape of adrenocortical carcinomas may occur because of altered Fas/Fas-L system expression and loss of MHC class II expression.
87. 87 Dhabhar FS, McEwen BS: Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999, 96:1059-1064. The hormonal mediators of a stress-induced enhancement of skin immunity are identified. Adrenalectomy, which eliminates the glucocorticoid and epinephrine stress response, eliminated the stress-induced enhancement of skin delayed-type hypersensitivity (DTH). Low-dose corticosterone or epinephrine administration significantly enhanced skin DTH and produced a significant increase in the number of T cells in lymph nodes draining the site of the DTH reaction. In contrast, high-dose corticosterone, chronic corticosterone, or low-dose dexamethasone administration significantly suppressed skin DTH. These results suggest a role for adrenal stress hormones as endogenous immunoenhancing agents, and show that hormones released during an acute stress response may help prepare the immune system for potential challenges for which stress perception by the brain may serve as an early warning signal.
88. 88 Bornstein SR, Chrousos GP: Adrenocorticotropin (ACTH)-and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999, 84(5):1729-1736. Summarizes ACTH-independent mechanisms of adrenocortical regulation through the autonomic nervous system and the immune system. Its significance for both normal adrenal physiology and clinical medicine are addressed.
89. 89 Späth-Schwalbe E, Born J, Schrezenmeier H, et al.: Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994, 79(4):1212-1214.
90. 90 Nagano I, Takao T, Nanamiya W, et al.: Differential effects of one and repeated endotoxin treatment on pituitary-adrenocortical hormones in the mouse: role of interleukin-1 and tumor necrosis factor-α. Neuroimmunomodulation 1999, 6:284-292. A comparison of the effects of one-time and repeated endotoxin treatment on the pituitary-adrenal response and an evaluation of the role of IL-1-β and TNF-α in mediating the effects of lipopolysaccharides (LPS). Both cytokines appear important in modulating the ACTH and B responses to one endotoxin treatment. TNF-α may be important in modulating the attenuated pituitary adrenocortical response following 4-day endotoxin treatment, and IL-1-β appears to play a prominent role in attenuating the response following 8-day endotoxin treatment. The effects of cytokines on the HPA axis may be mediated at all levels, including the brain and pituitary gland, as well as having direct effects at the adrenal level.
91. 91 Gatti G, Masera RG, Pallavicini L, et al.: Interplay in vitro between ACTH, β-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity. Brain Behavior Immunity 1993, 7:16-28.
92. 92 Masera RG, Staurenghi A, Sartori ML, Angeli A: Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome. Eur J Endocrinol 1999, 140:299-306. Excess endogenous glucocorticoids affect spontaneous natural killer cell activity and responsiveness to exogenous IFN-γ or cortisol. The differential patterns observed between pituitary-dependent and adrenal-dependent groups are compatible with a positive immunomodulatory role of pituitary pro-opiomelanocortin-derived peptides that effectively counterbalance, at least partially, glucocorticoid immunosuppression.
93. 93 Bornstein SR, Stratakis CA, Chrousos GP: Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 1999, 130:759-771. A report on new aspects of adrenocortical tumongenesis and their clinical implications, and recent advances in the diagnosis and management of adrenocortical tumors.
94. 94 Bornstein SR, Vaudry H: Paracrine and neuroendocrine regulation of the adrenal gland-basic and clinical aspects. Horm Metab Res 1998, 30:292-296.
95. 95 N'Diaye N, Tremblay J, Harnet P, Lacroix A: Hormone receptor abnormalities in adrenal Cushing's syndrome. Horm Metab Res 1998, 30:440-446.
96. 96 Willenberg HS, Stratakis CA, Marx C, et al.: Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome. N Engl J Med 1998, 339(1):27-31.
97. 97 Jenkins PJ, Sohaib SA, Trainer PJ, et al.: Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy. Br J Cancer 1999, 80(11):1815-1819. A study in 14 patients with a variety of malignancies prior to receiving cytotoxic chemotherapy to examine the correlation between activity of the HPA axis in patients with malignancy and the size of the adrenal glands. Malignancy is associated with diffuse enlargement of the adrenal glands and resistance to dexamethasone-induced suppression of the HPA axis, which is not due to ectopic ACTH secretion.
98. 98 Cutolo M: Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic diseases. In: Neuroendocrine Immune Basis of the Rheumatic Diseases: Annals of the New York Academy of Sciences. Edited by Cutolo M. New York: New York Academy of Sciences, 1999:876. On the basis of a more complete understanding of macrophage effector and immunoregulatory activities, on both a local and a systemic level, new hopes arise from the possible development of more sophisticated antimacrophage treatments for the management of autoimmune rheumatic diseases.
99. 99 Masi AT, Da Silva JAP, Cutolo M: Perturbations of the hypothalamic pituitary gonadal axis in rheumatoid arthritis. Baillière Clin Rheumatol 1996, 10:295-331.
100. 100 Straub RH, Westermann J, Scholmerich J, Falk W: Dialogue between the CMS and the immune system in lymphoid organs. Immunol Today 1998, 19(9):409-413.
101. 101 Straub RH, Vogl D, Gross V, et al.: Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998, 93(11):2197-2202.
102. 102 Marx C, Wolkersdorfer GW, Bornstein SR: A new view on immune-adrenal interactions: role for Fas and Fas ligand? Neuroimmunomodulation 1998, 5(1-2):5-8.
103. 103 Masi AT, Chrousos GP, Bornstein SR: Enigmas of adrenal androgen and glucocorticoid dissociation in premenopausal onset rheumatoid arthritis. J Rheumatol 1999, 26:247-250. Summarizes some of the recent work on adrenal androgens in rheumatoid arthritis. The possible mechanisms causing the dissociation of androgen and glucocorticoids in this disorder are discussed.
104. 104 Arlt W, Callies F, van Vlijmen JC, et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999, 341(14):1013-1020.
105. 105 Marx C, Wolkersdörfer GW, Brown JW, et al.: MHC class II expression-a new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 1996, 81(12):4488-91.